Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...
Pre-earnings options volume in Rani Therapeutics (RANI) Holdings is normal with calls leading puts 15:2. Implied volatility suggests the market is anticipating a move near 12.6%, or 30c, after results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback